Compare ORIS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIS | GLTO |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | Denmark |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 54.5M |
| IPO Year | 2024 | 2020 |
| Metric | ORIS | GLTO |
|---|---|---|
| Price | $1.42 | $30.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | ★ 479.4K | 214.0K |
| Earning Date | 04-30-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $12,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $171.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.11 | $2.01 |
| 52 Week High | $45.60 | $38.33 |
| Indicator | ORIS | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 57.99 |
| Support Level | $1.11 | $19.85 |
| Resistance Level | $1.30 | $30.03 |
| Average True Range (ATR) | 0.12 | 2.93 |
| MACD | -0.05 | 0.26 |
| Stochastic Oscillator | 34.62 | 90.32 |
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.